Supplementary Figure S1 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations | Synapse
September 16, 2024
Supplementary Figure S1 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Supplementary Figure 1. RLY-4008 is an irreversible inhibitor of FGFR2.